undamentalytics Newsletter
Sign in

Neuronetics, Inc. (STIM) stock

Add to watchlist

Add holding +

NASDAQ: STIM Nasdaq Health Care Equipment Next results ~November 4, 2026

C Fundamentals grade

Neuronetics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$7.4

Revenue-to-maturity cash-flow model

Base case. Range ~$5.8–$9.3 across our lower- and higher-growth cases (25%–35% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Neuronetics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 3 selling15 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
  • Funds45 adding, 53 cuttingOf 16 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Neuronetics files

Where Neuronetics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $155m, up 39.6% on a year earlier, slower than the 69.5% growth a quarter earlier. That growth ranks 4 of 58 among the health care equipment companies we cover. Free-cash-flow margin rose to -7.3% from -31.9% a year earlier. Operating margin widened to -14.7% from -34.4%. The diluted share count is up 43.0% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $7.54 a share, against a share price of $2.44.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Neuronetics, Inc.'s trailing-twelve-month revenue grew 39.6% year on year, with a free-cash-flow margin of -7.3%. Where it stands out: revenue growth of 39.6% ranks 18 of 129 health care equipment companies we cover. Where it lags: change in growth rate of -29.9pp ranks 121 of 129 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 39.6% (-29.9pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 39.6% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 19.7 points on a year ago.

Things to watch

  • Growth slowing. The growth rate is 29.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -14.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -7.3% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 43.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 115% and a beta of 2.1 against the S&P 500.
  • Gross margin slipping. Gross margin is down 7.0 points on a year ago.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.04 against an average estimate of -$0.12: beat by 65.1%
Revenue
$42m, up 9.1% on a year earlier
Share reaction
+47.9% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.11

Neuronetics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-8.4%
  • 1 week-8.0%
  • 1 month-4.6%
  • This year+49.3%
  • 1 year-22.3%
  • 5 years-62.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$155M
Operating margin
-14.7%
Net margin
-19.6%
EPS (TTM, diluted)
$-0.44

Growth

Revenue growth
+39.6%
Change in growth rate
−29.9 pts
Share count change
+43.0%

Cash

Free cash flow (TTM)
-$11.3M
FCF margin
-7.3%
Stock pay % of revenue
3.8%

Earnings

Last results
August 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Neuronetics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Neuronetics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.05 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$7.4 ~$5.8–$9.3 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$2.0 ~$2.4–$10 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.3 ~$2.0–$7.4 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Neuronetics, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025Now
Share price$19.35$4.49$11.11$4.46$6.87$2.90$1.61$1.38$2.06
Market value$693m$165m$419m$227m$370m$166m$102m$91m$144m
+ Net debt (− = net cash)−$74m−$45m−$14m−$59m−$34m$323000$42m$42m$46m
Enterprise value$618m$120m$405m$168m$335m$167m$144m$133m$189m
Multiples
Price / sales 13.1x2.6x8.5x4.1x5.7x2.3x1.4x0.6x0.9x
Price / earnings —————————
Price / free cash flow —————————
EV / EBITDA —————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

26 /100

Weak moat

How hard Neuronetics's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -21.6% of total assets over 8 years.

  • Pricing power 12 / 20

    Gross margin has been a median 75.2%, moving by 9.9 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -39.8%; its worst year was -57.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -39.5% of revenue.

  • Discipline 4 / 20

    The diluted share count rose 213.5% over five years; stock-based pay has been a median 6.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $40m and EPS of −$0.11 (range −$0.11 to −$0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.47 +20% $162m +9%
Next −$0.34 +28% $177m +9%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.4% on 90 days ago. In the last 30 days, 1 analyst raised Neuronetics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Neuronetics, Inc., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.46 Current fiscal year, 60 days ago: −$0.46 Current fiscal year, 30 days ago: −$0.47 Current fiscal year, 7 days ago: −$0.47 Current fiscal year, Now: −$0.47 −$0.47 Next fiscal year, 90 days ago: −$0.34 Next fiscal year, 60 days ago: −$0.34 Next fiscal year, 30 days ago: −$0.34 Next fiscal year, 7 days ago: −$0.34 Next fiscal year, Now: −$0.34 −$0.34

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.46−$0.34
60 days ago −$0.46−$0.34
30 days ago −$0.47−$0.34
7 days ago −$0.47−$0.34
Now −$0.47−$0.34

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.12 −$0.04 +65.1%
Mar 2026 −$0.17 −$0.15 +15.0%
Dec 2025 −$0.11 −$0.10 +9.1%
Sept 2025 −$0.12 −$0.13 −8.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026123
  3. Aug 2026224

Counts of recommendations published by analysts covering Neuronetics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
17.6%
of tradable shares
Days to cover
8.3
at average volume
Short interest, 1 month
+16%
to October 15, 2026
Held by institutions
54%
of shares
Held by insiders
32.8%
of shares
Employees
658
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −22.3%

$2.65 on October 31, 2025 to $2.06

ThenNowEffect
Revenue (last 12 months) $111m $155m +39.6%
P/S multiple 1.2x 0.9x −20.4%
Share count 49m 70m −30.1%

Biggest factor: share count. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
STIM−60%+54%−58%−45%−14%+49%
Industry peers (median)−7%−37%−8%−19%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
STIM33%50%25%42%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
STIM−82%−54%−85%−87%−77%−47%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 28, 2018: 98% from September 10, 2018 to November 13, 2024. Getting back needed a 6054% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.18 – $3.30
From 52-week high
−37.6%
vs 50-day average
−17.7%
vs 200-day average
+9.9%
Volatility (1 year)
115%
Beta vs S&P 500
2.13

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±22.9%
After a week
4 up, 8 down
typical move ±23.7%
After a month
4 up, 8 down
typical move ±35.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +47.9% −0.1% +45.2% +38.7%
May 5, 2026 −5.4% +2.2% −37.1% −27.7%
March 17, 2026 −0.7% −1.1% +7.0% +2.9%
February 10, 2026 +20.8% −0.3% −7.4% −14.8%
November 4, 2025 −1.1% −0.8% −20.6% −47.7%
August 5, 2025 −8.9% +0.3% −17.2% −29.0%
May 6, 2025 +1.3% −0.4% −1.2% −14.9%
March 4, 2025 +27.2% −0.1% +6.6% −7.5%
January 13, 2025 +26.3% +0.3% +31.0% +132.5%
November 12, 2024 −44.5% −0.3% −31.4% +5.5%
August 12, 2024 −58.5% +1.7% −43.3% −58.3%
May 7, 2024 −32.0% +0.1% −36.3% −45.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Neuronetics, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Neuronetics, Inc.
$50M $100M $150M $200M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $69.2M Revenue (TTM), FY23 Q4: $71.3M Revenue (TTM), FY24 Q1: $73.2M Revenue (TTM), FY24 Q2: $72.1M Revenue (TTM), FY24 Q3: $72.7M Revenue (TTM), FY24 Q4: $74.9M Revenue (TTM), FY25 Q1: $89.4M Revenue (TTM), FY25 Q2: $111.1M Revenue (TTM), FY25 Q3: $129.9M Revenue (TTM), FY25 Q4: $149.2M Revenue (TTM), FY26 Q1: $151.6M Revenue (TTM), FY26 Q2: $155.1M $155.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $69.2M
FY23 Q4 $71.3M
FY24 Q1 $73.2M
FY24 Q2 $72.1M
FY24 Q3 $72.7M
FY24 Q4 $74.9M
FY25 Q1 $89.4M
FY25 Q2 $111.1M
FY25 Q3 $129.9M
FY25 Q4 $149.2M
FY26 Q1 $151.6M
FY26 Q2 $155.1M
Revenue growth, TTM YoY Neuronetics, Inc.
0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 11.6% Revenue growth, TTM YoY, FY23 Q4: 9.4% Revenue growth, TTM YoY, FY24 Q1: 10.0% Revenue growth, TTM YoY, FY24 Q2: 6.2% Revenue growth, TTM YoY, FY24 Q3: 5.0% Revenue growth, TTM YoY, FY24 Q4: 5.0% Revenue growth, TTM YoY, FY25 Q1: 22.2% Revenue growth, TTM YoY, FY25 Q2: 54.2% Revenue growth, TTM YoY, FY25 Q3: 78.6% Revenue growth, TTM YoY, FY25 Q4: 99.2% Revenue growth, TTM YoY, FY26 Q1: 69.5% Revenue growth, TTM YoY, FY26 Q2: 39.6% 39.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 11.6%
FY23 Q4 9.4%
FY24 Q1 10.0%
FY24 Q2 6.2%
FY24 Q3 5.0%
FY24 Q4 5.0%
FY25 Q1 22.2%
FY25 Q2 54.2%
FY25 Q3 78.6%
FY25 Q4 99.2%
FY26 Q1 69.5%
FY26 Q2 39.6%
Operating margin (TTM) Neuronetics, Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -48.9% Operating margin (TTM), FY23 Q4: -42.8% Operating margin (TTM), FY24 Q1: -37.6% Operating margin (TTM), FY24 Q2: -39.8% Operating margin (TTM), FY24 Q3: -37.8% Operating margin (TTM), FY24 Q4: -46.2% Operating margin (TTM), FY25 Q1: -43.3% Operating margin (TTM), FY25 Q2: -34.4% Operating margin (TTM), FY25 Q3: -29.2% Operating margin (TTM), FY25 Q4: -21.1% Operating margin (TTM), FY26 Q1: -19.4% Operating margin (TTM), FY26 Q2: -14.7% -14.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -48.9%
FY23 Q4 -42.8%
FY24 Q1 -37.6%
FY24 Q2 -39.8%
FY24 Q3 -37.8%
FY24 Q4 -46.2%
FY25 Q1 -43.3%
FY25 Q2 -34.4%
FY25 Q3 -29.2%
FY25 Q4 -21.1%
FY26 Q1 -19.4%
FY26 Q2 -14.7%
FCF margin (TTM) Neuronetics, Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -56.7% FCF margin (TTM), FY23 Q4: -48.2% FCF margin (TTM), FY24 Q1: -42.8% FCF margin (TTM), FY24 Q2: -38.0% FCF margin (TTM), FY24 Q3: -31.0% FCF margin (TTM), FY24 Q4: -43.3% FCF margin (TTM), FY25 Q1: -41.7% FCF margin (TTM), FY25 Q2: -31.9% FCF margin (TTM), FY25 Q3: -23.5% FCF margin (TTM), FY25 Q4: -14.2% FCF margin (TTM), FY26 Q1: -9.0% FCF margin (TTM), FY26 Q2: -7.3% -7.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -56.7%
FY23 Q4 -48.2%
FY24 Q1 -42.8%
FY24 Q2 -38.0%
FY24 Q3 -31.0%
FY24 Q4 -43.3%
FY25 Q1 -41.7%
FY25 Q2 -31.9%
FY25 Q3 -23.5%
FY25 Q4 -14.2%
FY26 Q1 -9.0%
FY26 Q2 -7.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 34 40 53 63 49 55 65 71 75 149 155
Gross profit 28 31 40 47 38 44 50 52 54 72 76
EBITDA −9 −13 −19 −26 −21 −27 −33 −29 −32 −28 −20
Operating income −9 −14 −20 −27 −22 −28 −35 −31 −35 −31 −23
Net income −11 −16 −24 −29 −27 −31 −37 −30 −44 −39 −30
Diluted EPS −$19.24 −$21.59 −$0.67 −$0.79 −$0.73 −$0.61 −$0.69 −$0.53 −$0.69 −$0.59 −$0.44
Growth (year on year)
Revenue — +18.1% +30.5% +18.7% −21.4% +12.3% +17.9% +9.4% +5.0% +99.2% +39.6%
Margins
Gross margin 80.7% 76.2% 76.4% 75.4% 76.5% 78.9% 76.3% 72.5% 72.3% 48.5% 49.1%
EBITDA margin −25.3% −32.2% −35.9% −41.3% −43.4% −47.9% −51.3% −40.0% −43.4% −18.8% −13.2%
Operating margin −27.3% −33.7% −37.6% −43.0% −45.3% −49.8% −53.8% −42.8% −46.2% −21.1% −14.7%
Net margin −32.8% −39.7% −45.7% −46.4% −55.7% −56.4% −57.0% −42.3% −58.4% −26.1% −19.6%
Free-cash-flow margin −25.9% −29.0% −40.9% −49.9% −59.1% −54.8% −52.2% −48.2% −43.3% −14.2% −7.3%
Cash flow
Cash from operations −9 −11 −21 −30 −28 −28 −31 −32 −31 −20 −10
Capital spending 0 1 1 1 1 2 3 2 1 1 1
Free cash flow −9 −12 −22 −31 −29 −30 −34 −34 −32 −21 −11
Stock-based pay 0 0 2 3 4 8 9 7 6 7 6
Free cash flow after stock pay −9 −12 −23 −35 −34 −38 −43 −42 −38 −28 −17
Balance sheet
Cash 17 29 105 76 49 94 70 60 18 28 19
Total debt 0 30 30 31 35 35 36 60 60 70 65
Net debt (negative = net cash) −17 1 −74 −45 −14 −59 −34 0 42 42 46
Diluted shares — — 36m 37m 38m 51m 54m 57m 63m 66m 70m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 30, 2026
What it owns · $132m
Short-term assets $53mLonger-term assets $78m
What it owes, and who funded it · $128m
Short-term liabilities $28mLonger-term liabilities $82mShareholders' equity $18m
  • Short-term assets cover short-term liabilities $53m of assets due within a year against $28m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $53m short-term assets against $82m of longer-dated liabilities.
  • More cash than debt $19m of cash against $62m of debt.
  • Debt below 40% of shareholders' equity Debt is 345% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 41% to 345% over five years.
  • A year's operating cash flow covers at least 20% of debt −$10m of operating cash flow against $62m of debt.
  • Operating profit covers interest at least five times over Operating income of −$23m against $9m of interest.

From Neuronetics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+43.0%
year over year
R&D spending
3.8%
of revenue
Days sales outstanding
38 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated STIM INFU RXST BBNX LAKE ANIK Median
Revenue, last 12 months $155m $143m $128m $127m $191m $121m $99m
Revenue growth, last 12 months 39.6% 2.5% −13.2% 43.7% −0.3% 5.3% 9.2%
Revenue growth, 3-year average 31.7% 6.6% 23.9% — 17.0% 0.3% 13.5%
Revenue growth, latest quarter 9.1% 2.6% 0.3% 30.3% −4.5% 15.6% 10.2%
Gross margin 49.1% 57.5% 77.5% 58.6% 32.6% 62.2% 61.2%
Operating margin −14.7% 9.3% −43.2% −72.7% −4.1% −4.2% −8.5%
Operating margin, 3-year average −29.7% 6.6% −36.3% — −4.4% 0.2% −17.9%
Net margin −19.6% 6.0% −36.8% −65.3% −14.0% −3.1% −12.0%
Cash from operations / revenue −6.7% 16.3% −17.8% −46.6% −0.4% 5.0% −1.9%
Free-cash-flow margin −7.3% 16.0% −21.3% −51.8% −0.3% 0.5% −3.9%
Free-cash-flow margin, 3-year average −25.7% 14.2% −22.1% — −4.1% 0.4% −7.0%
Stock pay / revenue 3.8% 3.5% 24.6% 18.4% 1.6% 10.9% 6.1%
Change in share count 43.0% −2.4% 2.2% 44.6% 14.1% −4.0% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 39.6% 9.1% 18 of 129
Change in growth rate Growth -29.9pp -0.6pp 121 of 129
Gross margin Profitability 49.1% 61.9% 87 of 123
Operating margin Profitability -14.7% -8.3% 74 of 132
Net margin Profitability -19.6% -12.0% 75 of 133
Free-cash-flow margin Cash generation -7.3% -3.4% 71 of 128
Stock pay as % of revenue Cash generation 3.8% 6.1% 51 of 123
Long-term debt as % of assets Balance sheet 46.8% 24.2% 73 of 87
Change in share count Balance sheet 43.0% 3.3% 102 of 115
Days sales outstanding Balance sheet 38 days 57 days 17 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Clinical Services $87M 58.3% ▲ 1856.7%
Medical Device $62.2M 41.7% ▼ 11.7%
Products and services
Line of business Revenue Share YoY
Services $87M 58.3% ▲ 1856.7%
Products $62.2M 41.7% ▼ 11.7%

From Neuronetics, Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$48.4M
Institutions reporting
87
Shares held vs prior quarter
▼ 10.6%
Positions opened / closed
16 / 28

Top buyers and sellers, Q2 2026: 45 institutions bought and 53 sold ; the biggest buyer was Wexford Capital LP (+1.3M shares) and the biggest seller Balyasny Asset Management L.P (−2.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Madryn Asset Management, LP $24.1M 18.5M 49.8% ▲ 0.3%
UBS Group AG $3M 2.3M 6.1% ▼ 20.6%
Wexford Capital LP $2.6M 2.0M 5.4% ▲ 185.7%
Fourworld Capital Management LLC $2.3M 1.7M 4.7% ▲ 17.1%
Lane Generational LLC $2.1M 1.6M 4.4% ▼ 8.0%
Vanguard Capital Management LLC $2M 1.5M 4.0% ▼ 26.4%
Masters Capital Management LLC $1.3M 1.0M 2.7% 0.0%
Advisorshares Investments LLC $965,634 743K 2.0% ▲ 20.4%
Ikarian Capital, LLC $911,537 701K 1.9% 0.0%
Blackrock, Inc. $775,608 597K 1.6% ▼ 74.3%
Hightower Advisors, LLC $732,863 564K 1.5% ▲ 0.2%
Marshall Wace, LLP $631,400 486K 1.3% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Neuronetics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $4.9M 15 trades by 1 insider, last 12 months Insider sales History → $281,887 11 trades by 3 insiders · 0% under pre-set plans
Net ▲ $4.6M net buying
Insider Date Trade Shares Price Value
Chernett Jorey 10% owner October 30, 2026 Buy 18,000 $2.27 $40,860
Chernett Jorey 10% owner August 14, 2026 Buy 14,000 $3.16 $44,240
Chernett Jorey 10% owner July 14, 2026 Buy 35,000 $1.78 $62,300
Chernett Jorey 10% owner May 19, 2026 Buy 100,000 $1.17 $117,000
Chernett Jorey 10% owner May 12, 2026 Buy 475,000 $1.34 $636,500
Chernett Jorey 10% owner April 21, 2026 Buy 100,000 $1.51 $151,000
Chernett Jorey 10% owner April 20, 2026 Buy 100,000 $1.58 $158,000
Chernett Jorey 10% owner March 30, 2026 Buy 385,442 $1.25 $481,802
Chernett Jorey 10% owner March 27, 2026 Buy 500,000 $1.35 $675,000
Chernett Jorey 10% owner March 26, 2026 Buy 25,000 $1.44 $36,000
Chernett Jorey 10% owner March 25, 2026 Buy 125,000 $1.40 $175,000
Chernett Jorey 10% owner March 20, 2026 Buy 169,472 $1.41 $238,956

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 27, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 5, 2026
  • March 17, 2026
  • February 10, 2026
  • November 4, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Neuronetics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Neuronetics, Inc. in brief

What does Neuronetics, Inc. do?
Neuronetics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Neuronetics, Inc.'s stock ticker?
Neuronetics, Inc. trades under the ticker STIM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Neuronetics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Neuronetics, Inc. reported revenue of $155M, 39.6% higher than a year earlier, according to its SEC filings.
What is Neuronetics, Inc.'s free cash flow?
Neuronetics, Inc.'s free-cash-flow margin is -7.3% of revenue over the trailing twelve months, ranking 71 of the 128 health care equipment companies we cover.
Who are Neuronetics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Madryn Asset Management, LP, UBS Group AG and Wexford Capital LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Neuronetics, Inc.'s market cap?
On November 2, 2026, Neuronetics, Inc.'s market capitalisation was about $144M and net debt of $45.8M. Market figures come from third-party market data and may be delayed.
How much debt does Neuronetics, Inc. have?
Neuronetics, Inc.'s debt-to-equity ratio is 344.6%, from its latest balance sheet (41.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Neuronetics, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Neuronetics, Inc. are Infusystem Holdings, Inc, Rxsight, Inc., Beta Bionics, Inc., Lakeland Industries Inc and Anika Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Neuronetics, Inc.'s.
Are insiders buying or selling Neuronetics, Inc. stock?
Over the last 12 months, Neuronetics, Inc.'s directors and officers reported 15 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
When is Neuronetics, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Neuronetics, Inc. announces its own schedule.